Biophytis S.A. Asset Resilience Ratio

Latest as of June 2025: 16.07%

Biophytis S.A. asset resilience ratio. Biophytis S.A. (ALBPS) has an Asset Resilience Ratio of 16.07% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biophytis S.A. (ALBPS) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€1.06 Million
≈ $1.24 Million USD Cash + Short-term Investments

Total Assets

€6.62 Million
≈ $7.74 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Biophytis S.A. (2012–2024)

Asset resilience ratio of Biophytis S.A. from 2012 to 2024. This chart shows how Biophytis S.A.'s Asset Resilience Ratio has changed over time. Read Biophytis S.A. total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Biophytis S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Biophytis S.A. (ALBPS) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €850.00K 12.83%
Short-term Investments €214.00K 3.23%
Total Liquid Assets €1.06 Million 16.07%

Asset Resilience Insights

  • Good Liquidity Position: Biophytis S.A. maintains a healthy 16.07% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Biophytis S.A. Industry Peers by Asset Resilience Ratio

Compare Biophytis S.A.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Biophytis S.A. Asset Resilience Ratio by Year (2012–2024)

Biophytis S.A. asset resilience ratio by year from 2012 to 2024. The table below shows the annual Asset Resilience Ratio data for Biophytis S.A..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.75% €190.00K
≈ $222.13K
€6.90 Million
≈ $8.07 Million
-22.98pp
2023-12-31 25.74% €3.08 Million
≈ $3.60 Million
€11.96 Million
≈ $13.98 Million
+0.34pp
2022-12-31 25.39% €5.58 Million
≈ $6.53 Million
€21.99 Million
≈ $25.71 Million
+2.70pp
2021-12-31 22.69% €8.23 Million
≈ $9.62 Million
€36.26 Million
≈ $42.39 Million
-32.43pp
2020-12-31 55.13% €15.00 Million
≈ $17.54 Million
€27.21 Million
≈ $31.81 Million
+52.44pp
2019-12-31 2.69% €475.00K
≈ $555.32K
€17.67 Million
≈ $20.66 Million
-43.05pp
2018-12-31 45.74% €10.00 Million
≈ $11.69 Million
€21.86 Million
≈ $25.56 Million
+9.21pp
2016-12-31 36.53% €3.07 Million
≈ $3.58 Million
€8.39 Million
≈ $9.81 Million
+36.53pp
2015-12-31 0.00% €367.00
≈ $429.06
€13.52 Million
≈ $15.80 Million
-24.83pp
2012-12-31 24.84% €300.49K
≈ $351.31K
€1.21 Million
≈ $1.41 Million
--
pp = percentage points

About Biophytis S.A.

PA:ALBPS France Biotechnology
Market Cap
$1.52 Million
€1.30 Million EUR
Market Cap Rank
#30328 Global
#559 in France
Share Price
€0.03
Change (1 day)
-7.78%
52-Week Range
€0.01 - €0.13
All Time High
€4896.00
About

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more